SCHEMBL2123135

SCHEMBL2123135

CC12CCC(OC1=O)C2(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 3/20 0.38
CYP3A4 P08684 3/20 0.38
MAPK1 P28482 3/20 0.38
HIF1A Q16665 2/20 0.38
CYP1A2 P05177 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
NFKB1 P19838 1/20 0.38
THPO P40225 1/20 0.38
PPM1B O75688 1/20 0.38
PTPN1 P18031 1/20 0.38
PPP1CC P36873 1/20 0.38
TFPI2 P48307 1/20 0.38
PPP5C P53041 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7098039 0.72 PTPN1 (0.39) LMNAMEN1MAPTKMT2AALDH1A1
SCHEMBL17893334 0.68 LMNA (0.39) LMNAMEN1MAPTKMT2AALDH1A1
SCHEMBL13809215 0.68 LMNA (0.39) LMNAMEN1MAPTKMT2AALDH1A1
SCHEMBL426068 0.68 LMNA (0.39) LMNAMEN1MAPTKMT2AALDH1A1
SCHEMBL7103950 0.68 LMNA (0.39) LMNAMEN1MAPTKMT2AALDH1A1
SCHEMBL7099395 0.68 LMNA (0.39) LMNAMEN1MAPTKMT2AALDH1A1
SCHEMBL13946305 0.68 LMNA (0.39) LMNAMEN1MAPTKMT2AALDH1A1
SCHEMBL2385770 0.67 LMNA (0.52) LMNAMEN1MAPTKMT2AALDH1A1
Methylamine SCHEMBL27490883 0.65 LMNA (0.37) LMNAMEN1MAPTKMT2AALDH1A1
SCHEMBL2245538 0.62 NR1I2 (0.47) LMNAMEN1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION V-BAC HOLDING CORP. (CA) 2015-09-24 US claimed
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2013-07-25 US claimed
US-7271192-B2 Substituted 2-pyrrolidine-2-yl-1H-indole compounds GRUENENTHAL GMBH (DE) 2007-09-18 US claimed
EP-1663962-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORP (US) 2007-08-22 EP claimed
EP-1451177-B1 SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE GRUENENTHAL GMBH (DE) 2007-03-21 EP claimed
JP-2007503392-A 2007-02-22 JP claimed
EP-1663962-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2006-06-07 EP claimed
JP-2005511694-A 2005-04-28 JP claimed
US-20050054651-A1 Compositions and methods for the treatment of disease associated with Trp-p8 expression DENDREON CORPORATION (US) 2005-03-10 US claimed
WO-2005020897-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2005-03-10 WO claimed
US-20050043369-A1 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections PROTEZ PHARMACEUTICALS INC. (US) 2005-02-24 US claimed
US-20050014815-A1 Substituted 2-pyrrolidine-2-yl-1H-indole compounds GRUENENTHAL GMBH (DE) 2005-01-20 US claimed
EP-1451177-A1 SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE Grünenthal GmbH (DE) 2004-09-01 EP claimed
US-20030225126-A1 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections INFLUX, INC. 2003-12-04 US claimed
WO-2003048156-A1 SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE Grünenthal GmbH (DE) 2003-06-12 WO claimed
EP-1296688-A2 BACTERICIDAL ANTIMICROBIAL METHODS AND COMPOSITIONS FOR USE IN TREATING GRAM POSITIVE INFECTIONS COMPRISING AN ANTIBIOTIC POTENTIATOR HAVING ACYL HYDRAZIDE, OXY AMIDE OR 8-HYDROXY QUINOLINE STRUCTURE Influx, Inc. (US) 2003-04-02 EP claimed
WO-2001070213-A2 BACTERICIDAL ANTIMICROBIAL METHODS AND COMPOSITIONS FOR USE IN TREATING GRAM POSITIVE INFECTIONS COMPRISING AN ANTIBIOTIC POTENTIATOR HAVING ACYL HYDRAZIDE OXY AMIDE OR 8-HYDROXY QUINOLINE STRUCTURE INFLUX, INC. (US) 2001-09-27 WO claimed
US-11693313-B2 Resist composition and method of forming resist pattern TOKYO OHKA KOGYO CO., LTD. (JP) 2023-07-04 US disclosed
EP-1296688-A2 BACTERICIDAL ANTIMICROBIAL METHODS AND COMPOSITIONS FOR USE IN TREATING GRAM POSITIVE INFECTIONS COMPRISING AN ANTIBIOTIC POTENTIATOR HAVING ACYL HYDRAZIDE, OXY AMIDE OR 8-HYDROXY QUINOLINE STRUCTURE Influx, Inc. (US) 2003-04-02 EP disclosed
WO-2001070213-A2 BACTERICIDAL ANTIMICROBIAL METHODS AND COMPOSITIONS FOR USE IN TREATING GRAM POSITIVE INFECTIONS COMPRISING AN ANTIBIOTIC POTENTIATOR HAVING ACYL HYDRAZIDE OXY AMIDE OR 8-HYDROXY QUINOLINE STRUCTURE INFLUX, INC. (US) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11693313-B2 Resist composition and method of forming resist pattern C1R, C1S, C9 LMNA 611/4885MEN1 1250/4885MAPT 3206/4885
US-20030225126-A1 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections NAAA, TLR8, OPA1 LMNA 3860/4885MEN1 4613/4885MAPT 4741/4885
US-20050014815-A1 Substituted 2-pyrrolidine-2-yl-1H-indole compounds IDO1, IDO2, TPH2 LMNA 2400/4885MEN1 2162/4885MAPT 697/4885
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 LMNA 2189/4885MEN1 2360/4885MAPT 2258/4885
US-20150266810-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 LMNA 2320/4885MEN1 2225/4885MAPT 2269/4885
US-20050043369-A1 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections NAAA, TLR8, OPA1 LMNA 3860/4885MEN1 4613/4885MAPT 4741/4885
US-20050054651-A1 Compositions and methods for the treatment of disease associated with Trp-p8 expression TRPC4, TRPC3, TRPC1 LMNA 1738/4885MEN1 2516/4885MAPT 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.